Deal overview

Deal overview
Price £80.00 Full version or £25.00 Light version
Publication Date Apr 09, 2018
Abstract On 9 April 2018, the quoted Swiss pharmaceutical group Novartis AG ("Novartis") announced a recommended offer for AveXis Inc ("AveXis"), a US-listed clinical-stage gene therapy company. The offer of $218 in cash per share valued 100% of AveXis at $8.65 billion. Completion of the transaction was expected in mid-2018, pending the successful completion of the offer and all ...
Number of pages (Full version) 8
Number of pages (Light version) 2
Format Adobe Acrobat (Download Acrobat Reader)
Free Sample Click Here to Download

Purchase this report

Accepted credit cards: Visa, America Express, Master Card

Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.

Search for Deals

Search over 70 million deal reports on more than 550,000 public and private companies. (copy)

Back to search results

Page Time: 0.014003s